Expert Interview
Discussing the potential of Corvus’ CPI-006 anti-CD73 antibody in treating advanced refractory cancer
Ticker(s): CRVSAn oncologist with experience on mainstream therapies and knowledge of CPI-006+CPI 444 combination therapy.
Please tell us about your clinical experience. How many patients do you currently treat with refractory cancer?
Added By: slingshot_insightsWhat are the implications of a dose-dependent increase in CPI-006 plasma exposure, 12 mg/kg having achieved complete and sustained occupancy of CD73 on peripheral blood lymphocytes?
Added By: slingshot_insightsIn the 1b trial, Infusions of CPI-006 resulted in activation and migration of B lymphocytes with changes in peripheral blood CD4 to CD8 ratios. However, detailed numbers are not specified. At what rate is this change beneficial?
Added By: slingshot_insightsWhat is your take on the CPI-006 + ciforadenant (CPI-444) combination’s efficacy? What are the pros and cons of blocking catalytic activity (conversion of adenosine) and stimulating immunomodulatory activity on CD73 positive cells?
Added By: slingshot_insightsHow much of a need is there for an anti-CD73 antibody targeting the adenosine pathway?
Added By: slingshot_insightsWhat percent of your patients fail standard therapies? What is your usual follow-up treatment plan?
Added By: slingshot_insightsHow likely would you be to put refractory cancer patients on CPI-006+ciforadenant in the future?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
